We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ESTA Shares Dip Despite FDA Filing for Motiva Breast Reconstruction
Read MoreHide Full Article
Key Takeaways
ESTA submitted Motiva implants to the FDA for primary and revision breast reconstruction.
ESTA aims to expand Motiva beyond elective augmentation into reimbursement-backed reconstruction care.
ESTA's filing is backed by a 274-patient IDE study across 17 U.S. sites and one in Europe.
Establishment Labs (ESTA - Free Report) recently announced that it has submitted its Motiva breast implants to the FDA for approval in primary and revision breast reconstruction. The filing builds on the company’s September 2024 FDA approval for breast augmentation and marks a key step toward expanding Motiva’s U.S. addressable market beyond elective procedures.
From an investor standpoint, the submission highlights Establishment Labs’ strategy to leverage its existing clinical data and early commercial traction to move into a less innovation-heavy segment of breast care. With reconstruction volumes tied to mastectomy procedures and reimbursement-driven demand, a successful approval could create a more durable growth lever over time, even as near-term stock movement reflects broader market sentiment rather than the long-term opportunity.
Likely Trend of ESTA Stock Following the News
Following the announcement, ESTA shares lost 4.6% at yesterday’s market closing. However, shares of the company have surged 70.7% in the last six-month period compared with the industry’s 6.4% growth. The S&P 500 has gained 14.5% in the same time frame.
If approved, the reconstruction indication could meaningfully strengthen Establishment Labs' business by expanding Motiva into a clinically necessary, reimbursement-backed market with steadier procedure volumes than elective augmentation. This would allow ESTA to deepen relationships with hospitals and cancer centers, drive higher implant utilization alongside its already approved Motiva Flora tissue expander, and diversify revenue toward more predictable demand, supporting longer-term growth and margin stability.
ESTA currently has a market capitalization of $2.22 billion. The company projects an earnings growth of 54.84% for the next year.
Image Source: Zacks Investment Research
More on the News
The FDA submission is supported by clinical data from the Motiva U.S. IDE Study, which evaluated the safety and performance of Motiva implants in post-mastectomy reconstruction patients across multiple geographies. The study enrolled 274 patients in total, including both primary and revision reconstruction cases, providing a broad data set covering different clinical scenarios. The trial was conducted at 17 sites in the United States and one in Western Europe, reflecting a diverse surgical and patient population relevant to real-world reconstruction settings.
The filing includes Motiva SmoothSilk Round and Ergonomix implants, which are differentiated by their patented SmoothSilk surface technology aimed at enhancing biocompatibility and reducing inflammatory response. The Ergonomix implant is designed to dynamically adapt to body position, shifting between a teardrop profile when standing and a round profile when lying down, while the Round implant maintains consistent shape and upper-pole fullness regardless of position.
Since gaining FDA approval for breast augmentation in 2024, more than 60,000 Motiva implants have been sold in the U.S. market. In reconstruction, Establishment Labs already has a commercial presence through the Motiva Flora tissue expander, which received U.S. clearance in 2023 and is currently used in over 200 cancer centers, featuring MRI-conditional capability enabled by integrated radio-frequency port technology.
Favorable Industry Prospects for ESTA
Per a report by Grand View Research, the global breast implants market size was estimated at $2.66 billion in 2024 and is projected to reach $5.16 billion by 2033, expanding at a CAGR of 7.7% from 2025 to 2033.
Market growth is attributed to the rising demand for aesthetic enhancement procedures, technological advancements in implant materials and increased awareness about body contouring solutions.
Other Recent Developments for ESTA
ESTA reported its third-quarter 2025 earnings in November, showcasing solid top-line growth and margin expansion. Total revenue rose to $53.8 million for the quarter ended Sept. 30, 2025, from $40.2 million in the prior-year period, reflecting stronger demand and improved pricing. Gross profit increased to $37.7 million, with gross margin expanding to 70.1% from 63.9% a year ago, driven mainly by favorable geographic mix and higher average selling prices.
ESTA’s Zacks Rank & Key Picks
Currently, ESTA carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Medpace Holdings (MEDP - Free Report) and Boston Scientific (BSX - Free Report) .
Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, posted a third-quarter 2025 adjusted EPS of $2.40, beating the Zacks Consensus Estimate by 20.6%. Revenues of $2.51 billion topped the Zacks Consensus Estimate by 3.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 11.9% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.34%.
Medpace, currently carrying a Zacks Rank #2 (Buy), reported a third-quarter 2025 EPS of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 14.28%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion topped the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ESTA Shares Dip Despite FDA Filing for Motiva Breast Reconstruction
Key Takeaways
Establishment Labs (ESTA - Free Report) recently announced that it has submitted its Motiva breast implants to the FDA for approval in primary and revision breast reconstruction. The filing builds on the company’s September 2024 FDA approval for breast augmentation and marks a key step toward expanding Motiva’s U.S. addressable market beyond elective procedures.
From an investor standpoint, the submission highlights Establishment Labs’ strategy to leverage its existing clinical data and early commercial traction to move into a less innovation-heavy segment of breast care. With reconstruction volumes tied to mastectomy procedures and reimbursement-driven demand, a successful approval could create a more durable growth lever over time, even as near-term stock movement reflects broader market sentiment rather than the long-term opportunity.
Likely Trend of ESTA Stock Following the News
Following the announcement, ESTA shares lost 4.6% at yesterday’s market closing. However, shares of the company have surged 70.7% in the last six-month period compared with the industry’s 6.4% growth. The S&P 500 has gained 14.5% in the same time frame.
If approved, the reconstruction indication could meaningfully strengthen Establishment Labs' business by expanding Motiva into a clinically necessary, reimbursement-backed market with steadier procedure volumes than elective augmentation. This would allow ESTA to deepen relationships with hospitals and cancer centers, drive higher implant utilization alongside its already approved Motiva Flora tissue expander, and diversify revenue toward more predictable demand, supporting longer-term growth and margin stability.
ESTA currently has a market capitalization of $2.22 billion. The company projects an earnings growth of 54.84% for the next year.
Image Source: Zacks Investment Research
More on the News
The FDA submission is supported by clinical data from the Motiva U.S. IDE Study, which evaluated the safety and performance of Motiva implants in post-mastectomy reconstruction patients across multiple geographies. The study enrolled 274 patients in total, including both primary and revision reconstruction cases, providing a broad data set covering different clinical scenarios. The trial was conducted at 17 sites in the United States and one in Western Europe, reflecting a diverse surgical and patient population relevant to real-world reconstruction settings.
The filing includes Motiva SmoothSilk Round and Ergonomix implants, which are differentiated by their patented SmoothSilk surface technology aimed at enhancing biocompatibility and reducing inflammatory response. The Ergonomix implant is designed to dynamically adapt to body position, shifting between a teardrop profile when standing and a round profile when lying down, while the Round implant maintains consistent shape and upper-pole fullness regardless of position.
Since gaining FDA approval for breast augmentation in 2024, more than 60,000 Motiva implants have been sold in the U.S. market. In reconstruction, Establishment Labs already has a commercial presence through the Motiva Flora tissue expander, which received U.S. clearance in 2023 and is currently used in over 200 cancer centers, featuring MRI-conditional capability enabled by integrated radio-frequency port technology.
Favorable Industry Prospects for ESTA
Per a report by Grand View Research, the global breast implants market size was estimated at $2.66 billion in 2024 and is projected to reach $5.16 billion by 2033, expanding at a CAGR of 7.7% from 2025 to 2033.
Market growth is attributed to the rising demand for aesthetic enhancement procedures, technological advancements in implant materials and increased awareness about body contouring solutions.
Other Recent Developments for ESTA
ESTA reported its third-quarter 2025 earnings in November, showcasing solid top-line growth and margin expansion. Total revenue rose to $53.8 million for the quarter ended Sept. 30, 2025, from $40.2 million in the prior-year period, reflecting stronger demand and improved pricing. Gross profit increased to $37.7 million, with gross margin expanding to 70.1% from 63.9% a year ago, driven mainly by favorable geographic mix and higher average selling prices.
ESTA’s Zacks Rank & Key Picks
Currently, ESTA carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Medpace Holdings (MEDP - Free Report) and Boston Scientific (BSX - Free Report) .
Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, posted a third-quarter 2025 adjusted EPS of $2.40, beating the Zacks Consensus Estimate by 20.6%. Revenues of $2.51 billion topped the Zacks Consensus Estimate by 3.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 11.9% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.34%.
Medpace, currently carrying a Zacks Rank #2 (Buy), reported a third-quarter 2025 EPS of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 14.28%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion topped the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.